Drugmaker Acer To Pay $8.35M To End Investor Suit

By Emilie Ruscoe (July 22, 2021, 6:41 PM EDT) -- Drugmaker Acer Therapeutics Inc. has agreed to pay $8.35 million to end investor claims that it misrepresented conversations it had with the U.S. Food and Drug Administration, which allegedly hurt investors when its share prices fell after the FDA rejected a new drug application the company had submitted....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!